Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation First-ever study to use objective MRI assessments to confirm presence of...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Ondo lancia Intelligent Portfolios, gestiti da BlackRock, integrando le strategie di portafoglio sulla blockchain
- Abre en Noruega el mayor centro de experiencia de servicios de NING en Europa
- Did Future FinTech Group Inc. Insiders Breach their Fiduciary Duties to Shareholders?
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →